Sarah Lee, CEO and co-founder of Relavo, won first place at the 2024 Ignite Health Fire Pitch Competition. Photo via Ignite/LinkedIn

A Houston organization that accelerates and supports female founders leading innovative health tech startups has concluded its 2024 program with the announcement of this year's top companies.

Ignite Health, an accelerator founded in 2017 by longtime Houston health care professional Ayse McCracken, named its 2024 winners at its annual Fire Pitch Competition in Houston last month. The companies pitched health tech solutions across lung health, renal therapy, breastfeeding tech, and more.

"This year’s competition was a culmination of passion, innovation, and hard work from the top startups in our 2024 Accelerator Program," reads a LinkedIn post from Ignite. "These trailblazing founders earned their spot on the stage by demonstrating exceptional leadership and the potential to revolutionize the healthcare industry with their solutions and devices."

First place winner was Sarah Lee, CEO and co-founder of Relavo, a New York-based company that's making home dialysis more effective, safer, and more affordable. Lee accepted awards from Johnson & Johnson and Wilson Sonsini Goodrich & Rosati.

Therese Canares, CEO and founder of CurieDx, took second place and won its awards from SWPDC - Southwest National Pediatric Device Innovation Consortium and Wilson Sonsini. CurieDx, based in Baltimore, Maryland, is creating remote diagnostic tools using smartphone technology.

In third place is Andrea Ippolito, CEO and founder of SimpliFed, a company focused on democratizing access to baby feeding and breastfeeding services through virtual care that's covered by insurance. The startup won awards from Texas Children's Hospital and Wilson Sonsini Goodrich & Rosati.

Three other finalists won other awards, including:

  • Kadambari Beelwar, CEO and co-founder, Henderson, Nevada-based Truss Health, which created an AI-powered sensor fusion platform that's designed to detect early signs of infection, won an award presented by Memorial Hermann Health System and Golden Seeds
  • Mimi Gendreau Kigawa, CEO and co-founder of New York-based Zeph Technologies, an AI-lung care company with technology for clinicians to deliver pulmonary care to patients with chronic respiratory disease, won an award presented by CU Innovations and Houston Methodist
  • Ashley Yesayan, CEO and co-founder, New York-based OneVillage, a software platform meant to support patients and family members through trying health events, won an award presented by CU Innovations

The companies were evaluated by the 2024 judges, which included: Allison Rhines, head of JLABS Houston; Andrew Truscott, global health technology lead at Accenture; Angela Shippy, senior physician executive at Amazon Web Services; Kimberly Muller, executive director of CU Innovations at University of Colorado Anschutz Medical Campus; Myra Davis, chief innovation and information officer at Texas Children's Hospital; and Winjie Tang Miao, senior executive vice president and COO of Texas Health Resources.

From health care to politics, here's who you need to know in Houston innovation this week. Courtesy photos

3 Houston innovators to know this week

Who's who

There's no summer slowdown in sight, as Houston's innovation world keeps turning. Texas Children's Hospital is amping up their attention to innovation — and so is the mayor. Meanwhile, a local software company just made a big hire. Here's what innovators you need to keep an eye on.

Myra Davis, senior vice president and chief information and innovation officer of Texas Children's Hospital

Myra Davis is responsible for Texas Children's Hospital's technology and innovation — two completely separate things, she says. Courtesy of TCH

Myra Davis wants you to realize that there's a difference between technology and innovation. As the chief information officer, she's been in charge of maintaining tech within the hospital system. However, her role has evolved to include innovation, which means thinking about what new elements TCH can bring in — or what existing elements can be improved or expanded. Read more about Davis and what TCH is up to.

Talin Bingham, CTO of Identity Automation

Talin Bingham has been named CTO of Houston-based Identity Automation. Courtesy of Identity Automation

The chief technology officer is a huge role when it comes to a software company's hierarchy. Houston-based Identity Automation just tasked Talin Bingham with the position. Bingham replaces co-founder Troy Moreland as CTO, and Moreland will support the company in an advisory capacity. Last summer, the company made a major acquisition and sees plenty of opportunities for growth. Read more about the new hire.

Mayor Sylvester Turner

Mayor Sylvester Turner gave his State of the City address on May 20. Natalie Harms/InnovationMap

Mayor Sylvester Turner and his team are innovators themselves, constantly coming up with new ideas to enhance and connect the city. The city's latest endeavor was announced last week at the Greater Houston Partnership's State of the City luncheon. Mayor Turner's idea is to have 50 corporations sponsor 50 Houston-area parks scattered across the city for five years. Up next is finding 49 more companies, since Scott McClelland of HEB offered up his company on the spot. Read the 5 things the mayor promised in the address.

Myra Davis is responsible for Texas Children's Hospital's technology and innovation — two completely separate things, she says. Courtesy of TCH

Texas Children's exec to help transform the hospital's approach to innovation

Featured innovator

A few months ago, Myra Davis got a whole other slew of responsibilities with the addition of just one word to her title: Innovation. The senior vice president and chief information and innovation officer of Texas Children's Hospital oversees a team of individuals not only focused on bringing in new technologies and ideas — but maintaining those processes.

Currently, the hospital is in a transition phase looking to better represent its ongoing innovation, as well as bring in new aspects of innovation. Along with Paola Álvarez-Malo, assistant vice president of strategic and business planning at TCH, Davis is looking to keep TCH at the forefront of hospital innovation and pediatric care.

Davis sat down with InnovationMap to discuss the hospital's transformation process and how, while the work together, technoogy and innovation bring two different things to the table.

InnovationMap: What has been your initial focus since assuming the “innovation” part of your title a few months ago?

Myra Davis: When I was appointed, I stepped back and asked myself how we can go about doing this. I knew it was more than the need for technology. We needed to begin to leverage data and a resource that can be agnostic to the organization to help drive strategy.

IM: Why is being both the innovation officer and the information officer important?

MD: Typically, an innovation officer would pass off a new technology to the information officer and hope that they keep it up. Innovation is more than technology. It's about change, and advocating for change in practices, how we hire, how we look at outcomes, and how we look at data. Innovation is radical disruption of how we do things today. It's a full-time job, and then it backs up into including startups and new companies.

IM: Where are you in the transition process?

MD: We're in a discovery phase, which is almost complete. It will drive an outcome of what the structure should look like for an organization of our size and magnitude, and what additional resources we need to have. For example, today to make an appointment, you need to call and make an appointment at the front desk. But we should be disrupting that process and leverage technology. We should have goals of decreasing calls moving forward. We don't yet have the structure to bring those ideas to the table, but that's where I see it going.

IM: How have you seen innovation become a bigger player in health care?

MD: Health care is always a service organization. We're here to serve patients and help them get better. I think clinically, there's always been a need to stay innovative because it's medicine. Now, we're seeing the need to infuse the behaviors of innovative thinking and acting in our operating models to meet the health care model of service. What I mean by that is the cost of care. The models must change because reimbursements are changing, populations are changing, the demand of patients have changed. When I started, we never had patients not wanting to come in for care. Now, patients are saying they don't want to come in because it costs too much. While there's been a plethora of technologies — we have a host of technology systems — but we're realizing we've only scratched the surface with the opportunities we have.

I often talk about the little "i" versus the big "i" in the word "innovation." The little "i" is leveraging what you have already — that's an innovative game changer. Then there's the big "i" and that's the commercialization of a product or partnering with a startup company and they go public. When we say innovation, most people think of that big "i" but it's a spectrum.

IM: What’s the big technology you see disrupting the health care industry?

MD: I think it's data science. It's a major breakthrough. For prescriptive, predictive, and descriptive reasons, we can't afford to keep doing things ourselves. The market is getting competitive, and we must get to decision making faster. You got to go with the data. You can't be so precise it keeps you from being creative, but you have to start with knowledge.

------

Portions of this interview have been edited.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.